Berlin – Schnittker Möllmann Partners (SMP) advised a consortium consisting of leading European life-science and technology investors in the context of the consortium's investment into the biotech company Tacalyx. Partners in the investor consortium, co-led by Boehringer Ingelheim Venture Fund and Kurma Partners / Idinvest Partners, also included High-Tech-Gründerfonds, Coparion and Creathor. The total volume of the financing round is EUR 7 million. The investors received comprehensive legal advice from a team led by SMP partners Martin Schaper and Benjamin Ullrich. Tacalyx says that they are planning to invest the fresh capital into further developing their research platform which is focused on cancer therapy.